We had a fantastic time at PAIRS 2025, held from April 9–12 at the Dubai World Trade Centre!
On March 14, 2025, Seledora® Coronary Scoring Balloon Catheter, developed by Mixin Medtech(Suzhou) Co., Ltd., a subsidiary of Kossel Medtech (Suzhou) Co., Ltd., received approval from the National Medical Products Administration (NMPA) for market launch (Registration No. 20253030586). Kossel's indep
On March 14, 2025, the Octoparms® II vena cava filter independently developed by Kossel Medtech (Suzhou) Co., Ltd. was approved by the National Drug Administration (NMPA). (registration number is 20253130576). In addition, the Seledora® coronary scoring balloon catheter developed by the subsidiary M
The MiStent coronary drug-eluting stent, an important overseas transformation project of Corecell Medical, has officially entered the Chinese market with two major advantages of "rapid healing and long-lasting efficacy", providing a new clinical option for PCI surgeries.This issue will introduce the
Mistent® coronary drug-eluting stent system, as an important overseas transformation project of Kossel Medical, has officially launched in the Chinese market with two advantages of "fast healing and long efficacy", providing a new clinical choice for PCI surgery.This article brings you the design st
Author: Zhejiang Pulmonary Embolism and Deep Vein Thrombosis Prevention and Treatment AllianceBackground and ObjectivesThe Expert Consensus on the Prevention and Treatment Management Guidelines for Pulmonary Embolism and Deep Vein Thrombosis in Zhejiang Provincial Hospitals is based on the construct
At the beginning of 2025, good news keeps coming. The two products, Selethru® PTCA Balloon Dilatation Catheter and Selethru® NC PTCA Balloon Dilatation Catheter independently developed by Kossel, were approved for listing in Pakistan at the end of 2024 and then approved for listing by the Central Dr
注: 建议图片大小150px*50px 
